PCT

Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer

Monday, September 20, 2021 - 2:12pm

RAANANA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma (Trigone), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the treatment of bladder cancer, today announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer.

Key Points: 
  • RAANANA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma (Trigone), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the treatment of bladder cancer, today announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer.
  • The collaboration will focus on local administration of 4C Biomeds anti 4CB-1 as an innovative treatment for high-grade non-muscle invasive bladder cancer.
  • Trigone Pharma, a pharmaceutical company dedicated to developing novel solutions that treat bladder cancers and urologic diseases, and 4C Biomed, an early-stage biomed R&D group specializing in immuno-oncology and auto-immunity today announced a strategic collaboration agreement to advance novel intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).
  • Trigone Pharma is dedicated to developing and commercializing novel therapeutics to treat patients suffering from interstitial cystitis/bladder pain syndrome (IC/BPS), bladder cancer (NMIBC), and other related bladder conditions.

Lightbridge Receives Notice of Allowance for Key Patent in Japan

Thursday, September 16, 2021 - 1:00pm

The newly issued patent is based on the 2015 Patent Cooperation Treaty (PCT) patent application and covers a mixed grid arrangement of metallic fuel rods inside a fuel assembly.

Key Points: 
  • The newly issued patent is based on the 2015 Patent Cooperation Treaty (PCT) patent application and covers a mixed grid arrangement of metallic fuel rods inside a fuel assembly.
  • Lightbridge Fuel has been designed to enhance the safety and economics of nuclear power for both existing and next-generation nuclear reactors.
  • Seth Grae, President and CEO of Lightbridge commented, We are pleased to have been granted this latest patent in Japan, which is an important market for Lightbridge.
  • This patent is the latest addition to our growing intellectual property portfolio and follows similar approvals in other markets worldwide.

DaVita Kidney Care Names New Chief Nursing Officer

Thursday, September 16, 2021 - 11:02am

DENVER, Sept. 16, 2021 /PRNewswire/ --During Nephrology Nurses Week, DaVita Kidney Care begins a new chapter for its nursing program by announcing Tina Livaudais as the kidney care provider's chief nursing officer (CNO).

Key Points: 
  • DENVER, Sept. 16, 2021 /PRNewswire/ --During Nephrology Nurses Week, DaVita Kidney Care begins a new chapter for its nursing program by announcing Tina Livaudais as the kidney care provider's chief nursing officer (CNO).
  • Livaudais began her career with DaVita in 1995 as a PCT while a student in nursing school at Louisiana State University.
  • DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally.
  • DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.To learn more, visit DaVita.com/About .

Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President

Wednesday, September 15, 2021 - 1:00pm

It is with great pleasure that we announce Andrews appointment as Celularitys President, said Dr. Hariri.

Key Points: 
  • It is with great pleasure that we announce Andrews appointment as Celularitys President, said Dr. Hariri.
  • Andrew and I trained together at the Weill Cornell Medical Center and have worked in cellular medicines on parallel paths for over 30 years, Dr. Hariri continued.
  • Dr. Pecora commented, I am excited to take on this new role at Celularity.
  • Dr. Pecora previously served as President of the Physician Enterprise, Chief Innovations Officer, and the Institutional Research Official of Hackensack Meridian Health.

Lobe Sciences Provides Corporate Update to Investors and Stakeholders

Monday, September 13, 2021 - 2:43pm

Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:
    Dear Fellow Shareholders and Psychedelic Medicine Enthusiasts,
    We are pleased to say that 2021 has been a busy and transformative year for the Company.
  • During 2021, we have made significant progress on several fronts, and completed our transition to an integrated pharmaceutical development company.
  • We believe that psychedelic based therapeutics will bring a new era of treatment for many illnesses where current therapies are insufficient or unavailable.
  • Lobe Sciences is a life sciences company focused on psychedelic medicines.

PureCycle announces partnership with Mitsui to develop ultra-pure recycled polypropylene plant in Japan

Monday, September 13, 2021 - 3:30pm

The proprietary process removes color, odor and other contaminants from recycled feedstock resulting in ultra-pure polypropylene suitable for any PP market.

Key Points: 
  • The proprietary process removes color, odor and other contaminants from recycled feedstock resulting in ultra-pure polypropylene suitable for any PP market.
  • Mitsui has over 5,600 employees and deploys talent around the globe to identify, develop, and grow businesses in collaboration with a global network of trusted partners.
  • Mitsui has built a strong and diverse core business portfolio covering the Mineral and Metal Resources, Energy, Machinery and Infrastructure, and Chemicals industries.
  • This press release contains forward-looking statements, including statements about the financial condition and prospects of PCT.

Filament Health to Webcast Live at Life Sciences Investor Forum September 16th

Monday, September 13, 2021 - 1:35pm

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

Key Points: 
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.
  • A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access.
  • Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer

Thursday, September 9, 2021 - 1:00pm

It assists applicants in seeking patent protection internationally for their inventions, helps patent offices with their patent granting decisions, and facilitates public access to a wealth of technical information relating to those inventions.

Key Points: 
  • It assists applicants in seeking patent protection internationally for their inventions, helps patent offices with their patent granting decisions, and facilitates public access to a wealth of technical information relating to those inventions.
  • The application, which was submitted jointly with MSD, is based on the Phase Ib olinvacimab and pembrolizumab combo trial in metastatic Triple-Negative Breast Cancer (mTNBC).
  • In early September 2021, PharmAbcine initiated a Phase II olinvacimab and pembrolizumab combo study for the treatment of mTNBC (metastatic Triple-Negative Breast Cancer) in Australia.
  • "We will move onto getting our patent secured in multiple countries with great needs for a cancer treatment."

ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments

Wednesday, September 1, 2021 - 1:30pm

The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421).

Key Points: 
  • The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421).
  • PDC-1421 is the active ingredient for both the companys MDD and ADHD drugs.
  • We believe that the PCT filings, which provide quick entries to PCT contracting countries, such as China, Japan and European Union, can facilitate the global IP protection of our important MDD and ADHD products, said Dr. Howard Doong, ABVC BioPharma chief executive officer.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.

Tasrif Pharmaceutical Announces Grant of U.S. Patent for Humanized Monoclonal Antibodies against the Poliovirus Receptor

Wednesday, August 25, 2021 - 5:00pm

BOSTON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Tasrif Pharmaceutical announces the grant of a US Patent related to its proprietary humanized monoclonal antibodies against the poliovirus receptor (a.k.a.

Key Points: 
  • BOSTON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Tasrif Pharmaceutical announces the grant of a US Patent related to its proprietary humanized monoclonal antibodies against the poliovirus receptor (a.k.a.
  • Poliovirus Receptor (PVR) is overexpressed on many malignancies including cancers of the brain, breast, colon and pancreas.
  • Tasrif Pharmaceuticals lead molecule, TSRF 786C is a potential best-in-class fully humanized IgG4 (S241P) monoclonal antibody against PVR.
  • Tasrif Pharmaceuticals humanized monoclonal antibodies against PVR have promise for targeted cancer immunotherapy.